

Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
You can purchase shares of Geron (NASDAQ:GERN) through any online brokerage.
Other companies in Geron’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Geron has a consensus price target of $5.08.
The stock price for Geron (NASDAQ: GERN) is $0.9325 last updated November 3, 2026 at 9:28 AM EST.
There are no upcoming dividends for Geron.
Geron does not have any upcoming earnings scheduled.
There is no upcoming split for Geron.
Geron is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with...